London Daily

Focus on the big picture.
Friday, Jan 09, 2026

Weight loss drug semaglutide approved for NHS use

Weight loss drug semaglutide approved for NHS use

A weight loss jab that has gained popularity in the US has been approved for use by the NHS in England.

The National Institute for Health and Care Excellence (NICE) concluded semaglutide, marketed as Wegovy, is safe, effective and affordable.

Delivered via an injection into the skin, the drug makes people feel fuller and more satisfied, so they eat less.

Famous personalities such as Elon Musk claim to have used it - with a "craze" allegedly developing in Hollywood.


Lifestyle changes


Based on evidence from clinical trials, NICE says semaglutide could help people reduce their weight by over 10%, if implemented alongside nutrition and lifestyle changes.

It will be recommended for use by people with at least one weight-related health condition, as well as those who have a body mass index (BMI) which puts them near the top of the obese range.

BMI is calculated by dividing an adult's weight in kilograms by the square of their height in metres.

Those who are lower on the obese BMI range - a BMI between 30 and 34.9kg/m2 - could also be offered the drug if they have a weight-related health condition. NICE lists these as someone who is pre-diabetic, has type 2 diabetes, high blood pressure, heart disease or obstructive sleep apnoea.

Once-weekly injections of Wegovy will have to be prescribed by a specialist, and an individual will only be able to take the drug for a maximum of two years.

Semaglutide is also found in the diabetes medicine Ozempic, but, unlike Ozempic - which is intended for those with type 2 diabetes - Wegovy is recommended specifically for weight loss.

The drug works as an appetite suppressant by mimicking a hormone called Glucagon-like peptide-1 (GLP-1). This intestinal hormone is released after eating and typically makes people feel fuller, so should help reduce overall calorie intake.

Kailey Wood runs a TikTok account sharing her weight loss journey


An article published last year in Variety suggested the diabetes medicine Ozempic, which contains semaglutide, is being used by some professionals in the film and entertainment industry to lose weight quickly.

It has become so popular that there are currently widespread shortages in the US and concerns for those people who rely on the drug for medical reasons.

Insurance companies in the US are refusing to cover its use among people who are not diabetic and not taking it as a prescribed medicine.


'Ozempic face'


Pharmaceutical company Novo Nordisk, which makes both Ozempic and Wegovy, says the products should only be used as recommended by a doctor.

Like all medication, semaglutide comes with side-effects and risks - including nausea, stomach pain, vomiting and diarrhoea.

In addition, rapid weight loss can also lead to the skin losing collagen and elastin, causing what Vogue Magazine has dubbed the gaunt "Ozempic face".

Kailey Wood, 36, has been taking Ozempic for seven months, after being prescribed the drug by her doctor in New York.

She tells the BBC that she has lost just under 30kg - going from obese to healthy in the BMI range.

Semaglutide injections will be approved under NICE guidance


"I have Polycystic Ovarian Syndrome (PCOS) and insulin resistance, but honestly I didn't really struggle with my weight until I hit my 30s - after I had my kids," she says.

"I was rapidly gaining weight. I had a personal trainer and was on every diet known to man - keto, low carbohydrate, intermittent fasting and nothing seemed to work,".

When Kailey went for tests with her doctor, she was told she had high blood pressure and high cholesterol and, due to the risks associated with PCOS, she was at risk of developing type 2 diabetes too.

"The long-term effects [of being obese] freaked me out having two daughters," she says.

"I just wanted to get to my best self - to show them what a healthy mum looks like; to get outside and play with them."

Kailey, who works for a tech start-up and runs her own TikTok page, says that people who want to use semaglutide need to know the drug does have side-effects.

"When you start taking this medication, your body almost goes into shock - you get headaches, nausea, tiredness," she explains.

"But your body starts to get used to it. You have to be mindful and listen to your body."

Kailey says those elements of the US media who promoting the drug as a "get skinny quick product" leave "a bad taste". She believes it sends the wrong message.

"What it's really doing is changing people's lives - treating the patient before they have the disease," she says.

Just over a quarter of adults in England are obese and around a third are overweight, according to official figures.

In the UK, obesity is thought to cost the NHS £6.1bn per year, government estimates show.

The drug semaglutide is currently under consultation in Scotland, with Wales expected to follow the NICE guidelines issued in England.

Helen Knight, director of medicines evaluation at NICE, said: "For some people losing weight is a real challenge, which is why a medicine like semaglutide is a welcome option.

"It won't be available to everyone. Our committee has made specific recommendations to ensure it remains value for money for the taxpayer."

Dr Duane Mellor, registered dietitian and senior lecturer at Aston Medical School, Aston University, said: "It is important to remember that living with a higher body weight or obesity is not a lifestyle choice, and people wanting to improve their health should be supported to do that.

"It is also clear that semaglutide is not intended to be a lifestyle weight-loss product in the UK. It is to be used for the purpose of improving health."

Anyone who is offered semaglutide on the NHS will be supported by specialist weight management services, including support from a dietitian.

Newsletter

Related Articles

0:00
0:00
Close
UK Prime Minister Starmer Reaffirms Support for Danish Sovereignty Over Greenland Amid U.S. Pressure
UK Support Bolsters U.S. Seizure of Russian-Flagged Tanker Marinera in Atlantic Strike on Sanctions Evasion
The Claim That Maduro’s Capture and Trial Violate International Law Is Either Legally Illiterate—or Deliberately Deceptive
UK Data Watchdog Probes Elon Musk’s X Over AI-Generated Grok Images Amid Surge in Non-Consensual Outputs
Prince Harry to Return to UK for Court Hearing Without Plans to Meet King Charles III
UK Confirms Support for US Seizure of Russian-Flagged Oil Tanker in North Atlantic
Béla Tarr, Visionary Hungarian Filmmaker, Dies at Seventy After Long Illness
UK and France Pledge Military Hubs Across Ukraine in Post-Ceasefire Security Plan
Prince Harry Poised to Regain UK Security Cover, Clearing Way for Family Visits
UK Junk Food Advertising Ban Faces Major Loophole Allowing Brand-Only Promotions
Maduro’s Arrest Without The Hague Tests International Law—and Trump’s Willingness to Break It
German Intelligence Secretly Intercepted Obama’s Air Force One Communications
The U.S. State Department’s account in Persian: “President Trump is a man of action. If you didn’t know it until now, now you do—do not play games with President Trump.”
Fake Mainstream Media Double Standard: Elon Musk Versus Mamdani
HSBC Leads 2026 Mortgage Rate Cuts as UK Lending Costs Ease
US Joint Chiefs Chairman Outlines How Operation Absolute Resolve Was Carried Out in Venezuela
Starmer Welcomes End of Maduro Era While Stressing International Law and UK Non-Involvement
Korean Beauty Turns Viral Skincare Into a Global Export Engine
UK Confirms Non-Involvement in U.S. Military Action Against Venezuela
UK Terror Watchdog Calls for Australian-Style Social Media Ban to Protect Teenagers
Iranian Protests Intensify as Another Revolutionary Guard Member Is Killed and Khamenei Blames the West
Delta Force Identified as Unit Behind U.S. Operation That Captured Venezuela’s President
Europe’s Luxury Sanctions Punish Russian Consumers While a Sanctions-Circumvention Industry Thrives
Berkshire’s Buffett-to-Abel Transition Tests Whether a One-Man Trust Model Can Survive as a System
Fraud in European Central Bank: Lagarde’s Hidden Pay Premium Exposes a Transparency Crisis at the European Central Bank
Trump Announces U.S. Large-Scale Strike on Venezuela, Declares President Maduro and Wife Captured
Tesla Loses EV Crown to China’s BYD After Annual Deliveries Decline in 2025
UK Manufacturing Growth Reaches 15-Month Peak as Output and Orders Improve in December
Beijing Threatened to Scrap UK–China Trade Talks After British Minister’s Taiwan Visit
Newly Released Files Reveal Tony Blair Pressured Officials Over Iraq Death Case Involving UK Soldiers
Top Stocks and Themes to Watch in 2026 as Markets Enter New Year with Fresh Momentum
No UK Curfew Ordered as Deepfake TikTok Falsely Attributes Decree to Prime Minister Starmer
Europe’s Largest Defence Groups Set to Return Nearly Five Billion Dollars to Shareholders in Twenty Twenty-Five
Abu Dhabi ‘Capital of Capital’: How Abu Dhabi Rose as a Sovereign Wealth Power
Diamonds Are Powering a New Quantum Revolution
Trump Threatens Strikes Against Iran if Nuclear Programme Is Restarted
Apple Escalates Legal Fight by Appealing £1.5 Billion UK Ruling Over App Store Fees
UK Debt Levels Sit Mid-Range Among Advanced Economies Despite Rising Pressures
UK Plans Royal Diplomacy with King Charles and Prince William to Reinvigorate Trade Talks with US
King Charles and Prince William Poised for Separate 2026 US Visits to Reinforce UK-US Trade and Diplomatic Ties
Apple Moves to Appeal UK Ruling Ordering £1.5 Billion in Customer Overcharge Damages
King Charles’s 2025 Christmas Message Tops UK Television Ratings on Christmas Day
The Battle Over the Internet Explodes: The United States Bars European Officials and Ignites a Diplomatic Crisis
Princesses Beatrice and Eugenie Join Royal Family at Sandringham Christmas Service
Fine Wine Investors Find Little Cheer in Third Year of Falls
UK Mortgage Rates Edge Lower as Bank of England Base Rate Cut Filters Through Lending Market
U.S. Supermarket Gives Customers Free Groceries for Christmas After Computer Glitch
Air India ‘Finds’ a Plane That Vanished 13 Years Ago
Caviar and Foie Gras? China Is Becoming a Luxury Food Powerhouse
Hong Kong Climbs to Second Globally in 2025 Tourism Rankings Behind Bangkok
×